Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

CING - Cingulate Inc. Latest News | Finranks

Home

CING

C

Cingulate Inc. (CING)

NCM – Real Time Price. Currency in USD

6.39

+0.11 (1.75%)

At close: Mar 27, 2026, 4:00 PM EDT

6.21

-0.18 (-2.82%)

After-hours: Mar 27, 2026, 7:57 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Why did Cingulate stock skyrocket today?

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients

Videos

No Data

There is no data to display

Press releases

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

23.10.2025

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients